Physician profile
Steve A Weber
NPI 1730196668
$1,647.82
in general payments reported to CMS, 2019-2025
19 companies · $70.38 in 2025
The $70.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $170 · 2021: $519 · 2022: $276 · 2023: $307 · 2024: $117 · 2025: $70.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $382.89 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $243.75 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $177.59 | 2019-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $164.02 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $105.26 | 2020-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $98.96 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $95.90 | 2019-2022 | |
| Exact Sciences Corporation | $63.08 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $51.53 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $44.78 | 2022-2023 | |
| Astellas Pharma US INC | $44.60 | 2023-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $33.61 | 2022-2023 | Rexulti |
| Abbvie INC. | $33.44 | 2022 | |
| Axsome Therapeutics, INC. | $30.01 | 2024-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $18.90 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.81 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $14.63 | 2024 | |
| Xeris Pharmaceuticals, INC. | $13.81 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.